For the quarter ending 2025-09-30, KTTA made $23,446 in revenue. -$3,019,119 in net income. Net profit margin of -12876.90%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,752,262 | 1,662,223 | ||
| Realized foreign currency translation loss from dissolution of subsidiaries | - | 0 | ||
| Research and development | 1,357,793 | 2,148,676 | ||
| Foreign currency gain | - | 29,290 | ||
| Loss from operations | -3,110,055 | -3,810,899 | ||
| Change in fair value of warrant liabilities | -46,870 | 8,436 | ||
| Foreign currency (loss) gain | -26,250 | - | ||
| Other income | 8,619 | 19,464 | ||
| Interest and dividends, net | 43,396 | 54,424 | ||
| Other income, net | 72,635 | 94,742 | ||
| Loss before income taxes | -3,037,420 | -3,716,157 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -3,037,420 | -3,716,157 | ||
| Foreign currency translation | 18,301 | 5,631 | ||
| Comprehensive loss | -3,019,119 | -3,710,526 | ||
| Basic loss per share (in dollars per share) | -0.41 | -0.66 | ||
| Diluted loss per share (in dollars per share) | -0.41 | -0.66 | ||
| Weighted-average common shares outstanding, basic (in shares) | 7,443,577 | 5,641,251 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 7,443,577 | 5,641,251 | ||
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)